Alphabet Inc.’s subsidiary, Bloomberg-Isomorphic Labs, has recently announced strategic research partnerships with Novartis AG and Eli Lilly & Co.
Under the agreement with Lilly, Isomorphic Labs is set to receive \(45 million in cash to collaborate on developing small molecule therapies targeting various objectives. In addition to the initial payment and potential structured royalties of up to the lower double digits on online sales, the company stands to gain performance-based step payments amounting to a total of \)1.7 billion.
Furthermore, Isomorphic Labs and Novartis have joined forces to explore small-molecule therapies for three undisclosed targets. As per official statements, the collaboration entails an upfront payment of \(37.5 million with the possibility of earning up to \)1.2 billion in performance-based milestone payments.
Fiona Marshall, the chair of biomedical research at Novartis, emphasized the significance of this partnership, stating, “This collaboration leverages the distinctive capabilities of our organizations, spanning AI, data technology, medicinal science, and profound disease domain expertise, to unlock new opportunities in AI-driven drug discovery.”
